Navigation Links
Leukemia Drug Breakthrough Study In New England Journal Of Medicine

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in re search and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt's sole mission is to contribute to the prevention and cure of cancer.


'"/>

Source:University Of South Florida Health Sciences Center


Related biology news :

1. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
2. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
3. Loosen up, DNA: Leukemia gene changes genetic packaging
4. Leukemia drug turns mini-molecules up, cancer genes down
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
7. Breakthrough isolating embryo-quality stem cells from blood
8. Breakthrough System for Understanding Ocean Plant Life Announced
9. Breakthrough: Scientists create worlds tiniest organic particles
10. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
11. Sciences Breakthrough of the Year: Watching evolution in action
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... Charlotte, NC (PRWEB) , ... February 10, 2016 ... ... highly anticipated expansion to their comprehensive training and support program, Sonalink™ remote monitoring. ... Sonablate® HIFU procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to ...
(Date:2/10/2016)... ... 10, 2016 , ... Curoverse announced today that the open-source, ... capabilities for managing and processing genomic and health data at petabyte scale. ... and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. “Microsoft ...
(Date:2/10/2016)... La Jolla CA (PRWEB) , ... February 10, 2016 , ... ... of new agents for the treatment of Alzheimer’s disease, announced today it has been ... to February 18th at the Breakers in Palm Beach, Florida. The purpose of ...
(Date:2/9/2016)... PA (PRWEB) , ... February 09, 2016 , ... With ... the 2016 Wharton Health Care Business Conference will bring together over 500 top healthcare ... for an industry in transformation. The conference, organized by MBA students of the University ...
Breaking Biology Technology: